home / stock / rgnx / rgnx quote
Last: | $16.11 |
---|---|
Change Percent: | 1.64% |
Open: | $16.75 |
Close: | $16.11 |
High: | $16.815 |
Low: | $16.05 |
Volume: | 560,427 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.11 | $16.75 | $16.11 | $16.815 | $16.05 | 560,427 | 04-18-2024 |
$17.03 | $17.59 | $17.03 | $17.99 | $16.99 | 413,623 | 04-17-2024 |
$17.5 | $17.83 | $17.5 | $18.24 | $17.48 | 295,968 | 04-16-2024 |
$18.02 | $18.07 | $18.02 | $18.65 | $17.82 | 346,015 | 04-15-2024 |
$18.09 | $19.02 | $18.09 | $19.38 | $17.63 | 542,760 | 04-12-2024 |
$19.02 | $19.12 | $19.02 | $19.12 | $18.48 | 362,281 | 04-11-2024 |
$18.85 | $18.14 | $18.85 | $19.09 | $18.14 | 606,178 | 04-10-2024 |
$19.01 | $19.2 | $19.01 | $19.77 | $18.73 | 266,157 | 04-09-2024 |
$19.19 | $19.22 | $19.19 | $19.42 | $18.79 | 288,378 | 04-08-2024 |
$19.17 | $18.94 | $19.17 | $19.875 | $18.6 | 424,739 | 04-05-2024 |
$19.15 | $20.32 | $19.15 | $20.77 | $19.06 | 714,130 | 04-04-2024 |
$20.25 | $20.02 | $20.25 | $20.6499 | $19.82 | 540,244 | 04-03-2024 |
$20.29 | $21.17 | $20.29 | $21.19 | $20.16 | 547,641 | 04-02-2024 |
$21.53 | $21.08 | $21.53 | $21.57 | $20.65 | 536,571 | 04-01-2024 |
$21.07 | $22.33 | $21.07 | $22.42 | $20.94 | 487,057 | 03-29-2024 |
$21.07 | $22.33 | $21.07 | $22.42 | $20.94 | 487,057 | 03-28-2024 |
$22.18 | $21.79 | $22.18 | $22.3838 | $21.4273 | 561,385 | 03-27-2024 |
$21.67 | $21.88 | $21.67 | $22.31 | $21.47 | 345,696 | 03-26-2024 |
$21.59 | $21.81 | $21.59 | $22.25 | $21.13 | 302,600 | 03-25-2024 |
$21.78 | $22.49 | $21.78 | $22.84 | $21.75 | 279,146 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustain...
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrop...
2024-03-13 08:00:00 ET Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystr...